Celsion to Present New Data from OVATION Trial at Ovarian Cancer Meeting
News
All newly diagnosed ovarian cancer patients enrolled in the OVATION Phase 1b trial (NCT02480374) to date benefited from the addition of GEN-1 to standard of care, according to Celsion, the drug’s developer. ... Read more